Tyler Flores

A surge in R&D is reshaping the diabetic retinopathy treatment landscape, with a robust pipeline of novel therapies poised to address limitations of current anti-VEGF treatments and improve patient outcomes.

New data reveals a potential slowdown in biomarker adoption for clinical trials. Is this a temporary shift, or a sign of deeper challenges hindering personalized medicine's progress? We dive into the trends and implications.

New research highlights a burgeoning pipeline of therapies targeting cancer cachexia, a debilitating syndrome affecting millions. Investment is rising as innovative approaches move closer to market, offering potential relief for patients and growth opportunities for the industry.

New regulations in India and centralized procurement in China are driving significant changes in the pharmaceutical landscape, impacting supply chains, pricing, and investment strategies across emerging markets.

Venture capital investment in the pharmaceutical sector hit $5 billion in Q3 2025, driven by oncology's continued dominance. Investors are prioritizing de-risked assets and later-stage companies with robust clinical data.

A new report signals growing investment in social anxiety disorder (SAD) research, with clinical trials expanding globally. We examine the market trends, pipeline drugs, and regional disparities shaping this vital field.

European venture capital firm Medicxi closes its fifth fund, committing €500 million to an ‘asset-centric’ model aimed at accelerating drug development and driving returns in the biotech sector.

Sweden's Karolinska Development AB reports increased losses but sees progress within its portfolio companies, balancing investment in early-stage biotech with ongoing financial challenges. A deeper look at recent developments.

Canadian biotech Appili Therapeutics is doubling down on a unique strategy – securing government grants and contracts to fund its infectious disease research, aiming to minimize shareholder dilution and address critical unmet medical needs.

Data from Phase 1 trials suggest SAB-142 could offer a new approach to treating Type 1 Diabetes, potentially preserving insulin-producing cells without prolonged immunosuppression. The company is now advancing into a pivotal Phase 2b trial.

Positive early trial data for Aptose Biosciences’ acute myeloid leukemia treatment, tuspetinib, is tempered by ongoing financial challenges and reliance on a single funding source. Can the biotech survive long enough to bring its therapy to market?

Positive Phase 2 data for Alumis’s envudeucitinib offers a new potential treatment for psoriasis, with a focus on selective TYK2 inhibition. The drug is poised to compete with established biologics and emerging oral therapies.

Senti Bio presents encouraging Phase 1 data for its novel AML therapy, SENTI-202, but faces a critical funding shortfall. Can this innovative gene-circuit technology overcome significant financial headwinds?

Clinical trial advancements and a robust platform for drug discovery position Acrivon Therapeutics as a key player in precision oncology. New data offers hope for patients battling endometrial cancer.

Biotech firm Trevi Therapeutics reports strong Q3 financials and positive clinical trial data, paving the way for potential first-in-class treatment for chronic cough conditions like IPF and RCC.

Biotech firm Calidi Biotherapeutics reports positive preclinical results for its RedTail platform and lead candidate, CLD-401, alongside a successful funding round. The company aims to revolutionize cancer treatment through systemic targeted genetic medicine delivery.

Aardvark Therapeutics reports positive clinical trial progress for its Prader-Willi Syndrome treatment and unveils promising preclinical data for a novel obesity candidate designed to address limitations of existing GLP-1 RA therapies.

After navigating financial headwinds, Evofem Biosciences reports positive Q3 results, fueled by cost reductions and strategic shifts. Can the company maintain momentum and expand access to critical women’s health solutions?

Biotech firm Equillium has secured up to $50 million in funding to advance its lead candidate, EQ504, a novel therapy targeting ulcerative colitis. The company is betting on a new approach to immune modulation, shifting focus from previous programs.

Molecular diagnostics firm Co-Diagnostics reports widening losses and introduces a non-GAAP metric to assess performance, raising questions about its long-term viability as COVID-19 testing demand wanes.